New York, Feb 6, 2026, 09:50 EST — Regular session underway.
- ENSG climbed roughly 1.4% in early trading Friday, hitting close to $200.
- Ensign projects 2026 diluted EPS between $7.41 and $7.61, with revenue estimated at $5.77 to $5.84 billion.
- Truist’s David MacDonald hikes the price target to $215, highlighting occupancy improvements and a busy deal pipeline.
The Ensign Group’s stock jumped about 1.4% to $199.86 in early Friday trading, gaining $2.70 from Thursday’s close. The post-acute care operator unveiled its targets for 2026 and saw Wall Street boost its price target. 1
The timing is crucial. Post-acute care, which covers rehab and nursing services after hospital discharge, is a sector where shifts in bed occupancy and reimbursement rates can swiftly impact profits. Investors are now assessing how much of this momentum will extend into 2026.
Ensign’s guidance arrives amid ongoing challenges with staffing expenses and payer pressure in the sector, even as operators strive to boost occupancy. In this environment, a slight margin beat often carries more weight than a straightforward revenue beat.
Ensign reported total revenue of roughly $1.36 billion for the quarter ended Dec. 31, up from $1.13 billion the previous year. Net income attributable to Ensign came in at $95.5 million. The company said diluted earnings per share were $1.61 on a GAAP basis and $1.82 when adjusted. 1
Ensign projects diluted earnings between $7.41 and $7.61 per share for 2026, with revenue forecasted in the range of $5.77 billion to $5.84 billion. The company’s “adjusted” numbers exclude certain items it doesn’t consider core operating costs, such as stock-based compensation and specific charges. 2
Chief Executive Barry Port highlighted rising occupancy as well as what he described as room for more organic growth. “At 83%, we still have plenty of organic growth potential to keep driving earnings and revenue higher, even if acquisitions stopped,” Port said. This came after the company reported same-facility and transitioning occupancy rates of 83.8% and 84.9% for the quarter. 2
The company stayed focused on its acquisition narrative. Chief Investment Officer Chad Keetch revealed that Ensign added 17 operations during the quarter and since then, including 12 real estate assets. He also noted there are “several new additions lining up for the first quarter of 2026.” 2
Ensign wrapped the year with 378 healthcare operations spanning 17 states and held 160 real estate assets. Its Standard Bearer real estate unit accounted for 154 of those owned properties. The company also declared a quarterly cash dividend of $0.065 per share. 2
Chief Financial Officer Suzanne Snapper reported the company holds roughly $503.9 million in cash and has $591.6 million of unused capacity on its line of credit. 2
Other long-term care stocks gained in early trading. The Pennant Group edged up roughly 0.8%, Brookdale Senior Living jumped around 1.6%, and CareTrust REIT climbed close to 0.9%.
On Friday, Truist Securities analyst David MacDonald bumped up his price target for Ensign to $215 from $200 but maintained a hold rating, according to StreetInsider. 3
But the ramp isn’t straightforward. Ensign’s guidance counts on “normalized” insurance costs and management’s “current expectations” for reimbursement rates — and any shifts there could quickly erode margins in a business so reliant on Medicare and Medicaid. 2
Investors will soon dig into the company’s annual report, filed with the SEC on Feb. 4, searching for insights into its acquisition pipeline and real estate division. Traders are also keeping an eye out for deal announcements and closings before the March 31 quarter-end. The company noted its webcast replay will remain accessible until Feb. 27. 4
